1. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study. (18th September 2020) Authors: Yu, Li; Shi, Menghan; Cai, Qingqing; Strati, Paolo; Hagemeister, Fredrick; Zhai, Qiongli; Li, Ling; Fang, Xiaosheng; Li, Jianyong; Sun, Ruifang; Zhang, Shanxiang; Yang, Hanjin; Wang, Zhaoming; Qian, Wenbin; Iwaki, Noriko; Sato, Yasuharu; Zhang, Lu; Li, Jian; Oksenhendler, Eric; Xu‐Monette, Zijun Y. Journal: Oncologist Issue: Volume 25:Number 11(2020) Page Start: 963 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase 2 study of epothilone B analog BMS‐247550 (NSC 710428) in patients with relapsed aggressive non‐Hodgkin lymphomas. Issue 9 (10th January 2013) Authors: Churpek, Jane E.; Pro, Barbara; van Besien, Koen; Kline, Justin; Conner, Kathy; Wade, James L.; Hagemeister, Fredrick; Karrison, Theodore; Smith, Sonali M. Journal: Cancer Issue: Volume 119:Issue 9(2013) Page Start: 1683 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase 2 study of epothilone B analog BMS‐247550 (NSC 710428) in patients with relapsed aggressive non‐Hodgkin lymphomas. Issue 9 (10th January 2013) Authors: Churpek, Jane E.; Pro, Barbara; van Besien, Koen; Kline, Justin; Conner, Kathy; Wade, James L.; Hagemeister, Fredrick; Karrison, Theodore; Smith, Sonali M. Journal: Cancer Issue: Volume 119:Issue 9(2013) Page Start: 1683 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Issue 1 (2nd January 2022) Authors: Cherng, Hua-Jay J.; Chuang, Hubert H.; Steiner, Raphael; Fayad, Luis; Strati, Paolo; Nair, Ranjit; Hagemeister, Fredrick; Nastoupil, Loretta J.; Lee, Hun Ju; Neelapu, Sattva S.; Flowers, Christopher R.; Samaniego, Felipe; Rodriguez, Maria; Macapinlac, Homer A.; Feng, Lei; Westin, Jason Journal: Leukemia & lymphoma Issue: Volume 63:Issue 1(2022) Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A review of pathobiology and therapies for classic Hodgkin lymphoma. (September 2022) Authors: Khan, Maliha; Hagemeister, Fredrick; Wang, Michael; Ahmed, Sairah Journal: Blood reviews Issue: Volume 55(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Issue 2 (28th January 2020) Authors: Hu, Bei; Nastoupil, Loretta J.; Loghavi, Sanam; Westin, Jason R.; Thakral, Beenu; Fayad, Luis E.; Hagemeister, Fredrick; Neelapu, Sattva; Samaniego, Felipe; Lee, Hun J.; Wang, Michael L.; Fanale, Michelle; Fowler, Nathan; Oki, Yasuhiro Journal: Leukemia & lymphoma Issue: Volume 61:Issue 2(2020) Page Start: 328 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐Hodgkin lymphomas. (27th June 2013) Authors: Hagemeister, Fredrick; Rodriguez, Maria Alma; Deitcher, Steven R.; Younes, Anas; Fayad, Luis; Goy, Andre; Dang, Nam H.; Forman, Arthur; McLaughlin, Peter; Medeiros, Leonard Jeffrey; Pro, Barbara; Romaguera, Jorge; Samaniego, Felipe; Silverman, Jeffrey A.; Sarris, Andreas; Cabanillas, Fernando Journal: British journal of haematology Issue: Volume 162:Number 5(2013:Sep.) Page Start: 631 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma. (28th February 2019) Authors: Khashab, Tamer; Hagemeister, Fredrick; Romaguera, Jorge E.; Fanale, Michelle A.; Pro, Barbara; McLaughlin, Peter; Rodriguez, M. Alma; Neelapu, Sattva S.; Fayad, Luis; Younes, Anas; Feng, Lei; Vega, Francisco; Kwak, Larry W.; Samaniego, Felipe Journal: British journal of haematology Issue: Volume 185:Number 4(2019) Page Start: 670 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low‐grade B‐cell lymphomas. (31st March 2015) Authors: Samaniego, Felipe; Hagemeister, Fredrick; Romaguera, Jorge E.; Fanale, Michelle A.; Pro, Barbara; McLaughlin, Peter; Rodriguez, M. Alma; Neelapu, Sattva S.; Fayad, Luis; Younes, Anas; Feng, Lei; Berkova, Zuzana; Khashab, Tamer; Sehgal, Lalit; Vega‐Vasquez, Francisco; Kwak, Larry W. Journal: British journal of haematology Issue: Volume 169:Number 6(2015:Jun.) Page Start: 814 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T‐cell lymphoma. (17th April 2013) Authors: Oki, Yasuhiro; Younes, Anas; Copeland, Amanda; Hagemeister, Fredrick; Fayad, Luis E.; McLaughlin, Peter; Shah, Jatin; Fowler, Nathan; Romaguera, Jorge; Kwak, Larry W.; Pro, Barbara Journal: British journal of haematology Issue: Volume 162:Number 1(2013:Jul.) Page Start: 138 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗